Greenland Mines (NASDAQ: GRML) announced that IP Australia has granted Australian Patent No. 2023252508, covering gene therapy technology exclusively licensed by the company’s Biotech Division for the treatment of neuromuscular diseases through expression of the human Klotho protein. The patent strengthens the intellectual property supporting Greenland Mines’ Klotho-based therapeutic platform and includes claims covering gene therapy constructs, neuronal and induced pluripotent stem cells, and viral and non-viral delivery systems. The company said the patent further supports development of its KLTO-202 program targeting amyotrophic lateral sclerosis (“ALS”) and other neuromuscular disorders.
The patent grant marks a significant milestone for Greenland Mines’ biotech division, which is advancing a novel approach to treating devastating neuromuscular conditions. ALS, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, currently has limited treatment options. The Klotho protein, known for its anti-aging properties, has shown promise in preclinical studies for protecting neurons and improving muscle function. By securing patent protection in Australia, a key market for clinical development and potential commercialization, Greenland Mines is positioning itself to advance its KLTO-202 program toward human trials.
The intellectual property covers not only the gene therapy constructs but also delivery systems, both viral and non-viral, which could provide flexibility in developing treatments for various neuromuscular disorders beyond ALS. This broad coverage may create a competitive advantage for Greenland Mines as it seeks to partner with research institutions and pharmaceutical companies. The patent also includes claims related to neuronal and induced pluripotent stem cells, suggesting potential applications in regenerative medicine.
Greenland Mines operates two divisions: Mining, focused on exploration in Greenland, and Biotech, which includes the Klotho platform. The company’s strategy centers on building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision. However, the patent news underscores the potential value of its biotech assets, which could provide a significant upside for shareholders if the KLTO-202 program succeeds.
Investors should note that forward-looking statements in this announcement are subject to risks and uncertainties, including those set forth in the company’s filings with the SEC. The full press release is available at https://nnw.fm/PVbbH, and the latest news and updates relating to GRML are available in the company’s newsroom at https://ibn.fm/GRML.
The patent grant may also impact the broader gene therapy landscape, as Klotho-based treatments represent a new class of potential therapies for age-related and neurodegenerative diseases. If successful, Greenland Mines’ platform could offer hope to patients with ALS and other neuromuscular disorders, addressing a significant unmet medical need. The company’s ability to secure international patent protection strengthens its position in a competitive biotech sector and could attract interest from larger pharmaceutical companies seeking innovative gene therapy technologies.
